Dr. Pinaki Bose

Dr. Pinaki Bose, PhD

Positions

Assistant Professor

Cumming School of Medicine, Department of Biochemistry and Molecular Biology

Assistant Professor

Cumming School of Medicine, Department of Oncology

Member

Arnie Charbonneau Cancer Institute

Contact information

Phone number

Office: 403.220.8507
Lab: 403.220.8865

Location

Office: HMRB354

For media enquiries, contact

Kelly Johnston
Senior Communications Specialist

Please submit your media request here

 

Background

Biography

Dr. Pinaki Bose completed his Ph.D. in basic cancer research with Dr. Karl Riabowol at the University of Calgary, investigating the role of the ING1 tumour suppressor protein in DNA damage signaling and apoptosis. After completing his Ph.D., he joined the Ohlson Research Initiative (ORI) as a postdoctoral fellow and trained in the molecular epidemiology of head and neck cancers under the supervision of Drs. Joseph Dort and Nigel Brockton. As part of a second postdoctoral fellowship, he trained at the BC Cancer Agency (BCCA) Genome Sciences Centre in cancer genomics and bioinformatics under one of the leading bioinformaticians in the world, Dr. Steven Jones. Dr. Bose was also a member of the personalized oncogenomics (POG) program at the BCCA. The POG initiative administers targeted therapies to recurrent/metastatic cancer patients based on their genomic profiles.

Research

Areas of Research

Area of Focus
  • head and neck cancer
  • oral cancer
  • genomics
  • bioinformatics
Summary of Research

Dr. Bose currently directs the translational research program within the ORI, a multidisciplinary head and neck cancer research initiative working in close collaboration with surgeons, pathologists, bioinformaticians, statisticians and basic researchers. The Bose lab is investigating the biology of head and neck cancers with particular emphasis on mechanisms regulating lymph node metastasis (LNM). LNM is a potent predictor of worse prognosis in oral cancers, one of the most common cancers of the head and neck region. Towards this end, we are developing genome-wide screens in oral cancer cell lines and animal models to identify regulators of LNM.